Opinion|Videos|March 18, 2024
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer
Experts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
4
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
5